We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The COVID-19 vaccine Covaxin, which was approved for emergency use in India ahead of late-stage trial results, may be coming to the U.S., as its manufacturer, Bharat Biotech, has secured a U.S. partner and plans to seek Emergency Use Authorization (EUA) from the FDA for distribution in the U.S. Read More
St. Petersburg, Russia-based Pharmsynthez has reportedly begun manufacturing a generic version of Gilead Sciences’ COVID-19 antiviral treatment Veklury (remdesivir) without the U.S. company’s permission. Read More
As the U.S. impatiently awaits delivery of many more millions of doses of the two currently authorized COVID-19 vaccines, Pfizer/BioNTech and Moderna said they are confident that they can fully deliver what’s been ordered to date in the next few months — and that they have shipped around 59.4 million doses so far. Read More
Horizon Therapeutics plans to expand its rare disease therapy portfolio through the purchase of Viela Bio in a deal valued at over $3 billion. Read More
Prescription drug prices that Americans pay are 156 percent higher than the combined average in 32 other countries that are also members of the Organization for Economic Co-operation and Development (OECD), the RAND Corporation has reported in an HHS-funded study. Read More
At least one major drug distributor could join the fray to ship COVID-19 vaccine shots across the country and offer some slack to McKesson, the firm currently handling distribution of Moderna’s vaccine, as a third vaccine candidate appears close to authorization. Read More
Novartis CEO Vas Narasimhan said the company is looking to help other companies scale up production of COVID-19 vaccines and treatments and is currently in talks with “key players.” Read More
Novavax has announced interim results from a phase 3 UK trial that showed its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated 89.3 percent efficacy but faltered in a separate study that evaluated the vaccine for the South Africa variant. Read More